Who cares. The business model is fundamentally not suitable for the ASX. Eventually they will run out of idiots who are willing to tip money into this dumpster fire of a company.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%